{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:08:46Z","timestamp":1791396526584,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40265-014-0285-6","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T11:40:10Z","timestamp":1409744410000},"page":"1701-1707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Idelalisib: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,4]]},"reference":[{"issue":"11","key":"285_CR1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, Vos S, et al. PI3\u00a0K inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"N Engl J Med."},{"issue":"12","key":"285_CR2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078\u201388.","journal-title":"Blood."},{"key":"285_CR3","unstructured":"U.S. Food and Drug Administration. FDA approves Zydelig for three types of blood cancers [media release]. 2014. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm406387.htm ."},{"key":"285_CR4","unstructured":"Gilead Sciences Inc. ZYDELIG (idelalisib) US prescribing Information. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206545lbl.pdf . Accessed 31 Jul 2014."},{"issue":"1","key":"285_CR5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-013-0167-3","volume":"74","author":"F Cameron","year":"2014","unstructured":"Cameron F, McCormack PL. Obinutuzumab: first global approval. Drugs. 2014;74(1):147\u201354.","journal-title":"Drugs."},{"issue":"2","key":"285_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","volume":"74","author":"F Cameron","year":"2014","unstructured":"Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74(2):263\u201371.","journal-title":"Drugs."},{"key":"285_CR7","unstructured":"Agency EM. Summary of opinion (initial authorisation) Zydelig (idelalisib) [media release]. 24 July 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/003843\/WC500170181.pdf ."},{"key":"285_CR8","unstructured":"Gilead Sciences Inc. Gilead Sciences to Acquire Calistoga Pharmaceuticals for $US375 Million [media release]. 23 February 2011. http:\/\/www.gilead.com ."},{"key":"285_CR9","unstructured":"Diplomat. Diplomat receives distribution contract for Zydelig(R) (idelalisib) [media release]. 28 Jul 2014. http:\/\/www.diplomat.is ."},{"issue":"8","key":"285_CR10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012;119(8):1897\u2013900.","journal-title":"Blood."},{"issue":"22","key":"285_CR11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406\u201313.","journal-title":"Blood."},{"issue":"22","key":"285_CR12","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390\u20137.","journal-title":"Blood."},{"issue":"22","key":"285_CR13","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398\u2013405.","journal-title":"Blood."},{"key":"285_CR14","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. Pharmacokinetics and safety of idelalisib, a novel PI3K inhibitor, in Japanese and caucasian subjects [abstract no. 5575]. Blood. 2013;122(21).","DOI":"10.1158\/1538-7445.AM2014-CT217"},{"key":"285_CR15","unstructured":"Jin F, Robeson M, Zhou H, et al. Pharmacokinetics, metabolism and excretion of idelalisib. In: 55th Annual Meeting of the American Society of Hematology, ASH; 10\u201313 August 2013; New Orleans, LA."},{"key":"285_CR16","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. Evaluation of the effect of idelalisib on the QT\/QTC interval in healthy subjects [abstract no. 5573]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.5573.5573"},{"key":"285_CR17","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment [abstract no. 5572]. Blood. 2013;122(21).","DOI":"10.1158\/1538-7445.AM2014-CT204"},{"key":"285_CR18","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. In: 55th Annual Meeting of the American Society of Hematology, ASH; 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.5571.5571"},{"key":"285_CR19","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment [abstract no. 2592]. J Clin Oncol. (Meeting Abstracts). 2014;32(15 suppl. 1).","DOI":"10.1200\/jco.2014.32.15_suppl.2592"},{"key":"285_CR20","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. Drug interaction profile of idelalisib and its major metabolite, GS-563117 [abstract no. 2593]. J Clin Oncol. (Meeting Abstracts). 2014;32(15 suppl. 1).","DOI":"10.1200\/jco.2014.32.15_suppl.2593"},{"issue":"11","key":"285_CR21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med."},{"key":"285_CR22","doi-asserted-by":"crossref","unstructured":"Furman RR, De Vos S, Leonard JP, et al. A Phase 1 Study Of The Selective PI3Kdelta Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia [abstr. 4180]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7\u201310 December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.4180.4180"},{"key":"285_CR23","unstructured":"Barrientos JC, Wagner-Johnston ND, De Vos S, et al. Chemo-immunotherapy combination of idelalisib with bendamustine\/rituximab or chlorambucil\/rituximab in patients with relapsed\/refractory CLL demonstrates efficacy and tolerability. In: 55th Annual Meeting of the American Society of Hematology, ASH; 7\u201310 December 2013; New Orleans, LA."},{"key":"285_CR24","doi-asserted-by":"crossref","unstructured":"De Vos S, Furman RR, Barrientos JC, et al. Idelalisib, a Selective Inhibitor Of PI3K\u03b4, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL) [abstr. 2878]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7\u201310 December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.2878.2878"},{"key":"285_CR25","doi-asserted-by":"crossref","unstructured":"Coutre SE, Leonard JP, Barrimentos JC, et al. Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3K\u03b4, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)\/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation [abstr. 1632]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7\u201310 December 2014; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.1632.1632"},{"key":"285_CR26","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3K\u03b4) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naive patients \u226565\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Conference Presentation. 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.7005"},{"issue":"15 suppl. 1","key":"285_CR27","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/jco.2013.31.15_suppl.7005","volume":"31","author":"SM O\u2019Brien","year":"2013","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) 65\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol (Meeting Abstracts). 2013;31(15 suppl. 1):7005.","journal-title":"J Clin Oncol (Meeting Abstracts)."},{"issue":"15 suppl. 1","key":"285_CR28","doi-asserted-by":"crossref","first-page":"e19554","DOI":"10.1200\/jco.2014.32.15_suppl.e19554","volume":"32","author":"ND Wagner-Johnston","year":"2014","unstructured":"Wagner-Johnston ND, Gopal AK, Kahl BS, et al. Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL). J Clin Oncol (Meetings Abstracts). 2014;32(15 suppl. 1):e19554.","journal-title":"J Clin Oncol (Meetings Abstracts)."},{"key":"285_CR29","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston ND, De Vos S, Leonard J, et al. Preliminary results of PI3K\u03b4 inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine\/rituximab in patients with previously treated mantle cell lymphoma (MCL). Conference Presentation. 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.8501"},{"key":"285_CR30","unstructured":"Younes A, Moskowitz A, Moskowitz C, et al. PILOT phase 2 study of idelalisib, a selective inhibitor of PI3K\u03b4, in patients with heavily pretreated hodgkin lymphoma (HL). Conference presentation. 2013."},{"key":"285_CR31","doi-asserted-by":"crossref","unstructured":"Flinn I, Kimby E, Cotter FE, et al. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [abstract no. TPS7131]. J Clin Oncol. 2013;31(suppl.).","DOI":"10.1200\/jco.2013.31.15_suppl.tps7131"},{"key":"285_CR32","doi-asserted-by":"crossref","unstructured":"Eradat HA, Robak T, Delgado J, et al. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL) [abstract no. TPS7127]. J Clin Oncol. 2014;32(5 suppl.).","DOI":"10.1200\/jco.2014.32.15_suppl.tps7127"},{"key":"285_CR33","doi-asserted-by":"crossref","unstructured":"Salles GA, Lamanna N, Amin BR, et al. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia [abstract no. TPS7123]. J Clin Oncol. 2014;32(5 suppl.).","DOI":"10.1200\/jco.2014.32.15_suppl.tps7123"},{"key":"285_CR34","doi-asserted-by":"crossref","unstructured":"Salles GA, Ervin TJ, Dichmann R, et al. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) [abstract no. TPS8620]. J Clin Oncol. 2014;32(5 suppl.).","DOI":"10.1200\/jco.2014.32.15_suppl.tps8620"},{"key":"285_CR35","doi-asserted-by":"crossref","unstructured":"de Vos S, Sehn LH, Mulligan SP, et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) [abstract no. TPS8618]. J Clin Oncol. 2013;31(suppl.).","DOI":"10.1200\/jco.2013.31.15_suppl.tps8618"}],"updated-by":[{"DOI":"10.1007\/s40265-014-0310-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T00:00:00Z","timestamp":1412640000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0285-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0285-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0285-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T01:11:01Z","timestamp":1598231461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0285-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0285-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-014-0310-9","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}